IND-enabling safety tox studies for FDA submission in just 9 months
Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.
Developing a unique hybridoma platform for manufacturing mAb cocktail formulations
Learn how Syngene developed a unique hybridoma platform for manufacturing mAb cocktail formulations for use in reagent kits designed to activate and expand human T cells for immunotherapy in patients.